Healthcare stocks were advancing premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% higher and the iShares Biotechnology ETF (IBB) up 0.5%.
Mesoblast (MESO) shares were up more than 4% after the company said sales of its steroid-refractory acute graft-versus-host disease treatment, Ryoncil, totaled $36 million in fiscal Q4.
SL Science (SLBT) stock was up more than 8% after the company said it has submitted an orphan drug designation request to the US Food and Drug Administration for its Gamma Delta T therapy, named Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.
InMode (INMD) stock was up more than 1% after the company confirmed that its board has received an unsolicited acquisition proposal from Steel Partners Holdings dated July 9.